NYSE:ABBV - AbbVie Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $108.71
  • Forecasted Upside: 34.75 %
  • Number of Analysts: 19
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 14 Buy Ratings
  • 0 Strong Buy Ratings
$80.67
▲ +0.18 (0.22%)
1 month | 3 months | 12 months
Get New AbbVie Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABBV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABBV

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$108.71
▲ +34.75% Upside Potential
This price target is based on 19 analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $108.71, with a high forecast of $127.00 and a low forecast of $90.00. The average price target represents a 34.75% upside from the last price of $80.67.
Buy
The current consensus among 19 contributing investment analysts is to buy stock in AbbVie.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 4 sell ratings
5/8/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 2 sell ratings
8/6/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 2 sell ratings
11/4/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 2 sell ratings
2/2/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 1 sell ratings
5/2/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/29/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 1 sell ratings
10/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/23/2020TruistInitiated CoverageBuy$110.00Low
i
10/20/2020The Goldman Sachs GroupDowngradeNeutral ➝ SellHigh
i
10/16/2020JPMorgan Chase & Co.Boost Price TargetOverweight$115.00 ➝ $120.00Low
i
9/29/2020Berenberg BankInitiated CoverageHold$98.00Low
i
9/27/2020MizuhoReiterated RatingBuy$111.00Low
i
Rating by Vamil Divan at Mizuho
9/2/2020CitigroupBoost Price TargetBuy$98.00 ➝ $105.00Medium
i
8/20/2020Morgan StanleyBoost Price TargetOverweight$95.00 ➝ $108.00Medium
i
8/3/2020MizuhoBoost Price TargetBuy$110.00 ➝ $111.00Low
i
Rating by Vamil Divan at Mizuho
8/3/2020Royal Bank of CanadaBoost Price TargetOutperform$125.00 ➝ $127.00Low
i
Rating by Randall Stanicky at Royal Bank of Canada
6/29/2020MizuhoBoost Price TargetTop Pick ➝ Buy$101.00 ➝ $110.00Low
i
Rating by Vamil Divan at Mizuho
6/25/2020Royal Bank of CanadaBoost Price TargetOutperform$102.00 ➝ $125.00Medium
i
Rating by Randall Stanicky at Royal Bank of Canada
6/23/2020Atlantic SecuritiesUpgradeNeutral ➝ Overweight$115.00Medium
i
6/18/2020Royal Bank of CanadaReiterated RatingBuy$102.00Low
i
6/17/2020UBS GroupBoost Price Target$96.00 ➝ $109.00Low
i
6/10/2020Evercore ISIInitiated CoverageBuy$111.00High
i
Rating by Joshua Schimmer at Evercore ISI
6/10/2020Piper SandlerBoost Price Target$97.00 ➝ $110.00High
i
6/9/2020Wolfe ResearchUpgradePeer Perform ➝ OutperformLow
i
6/2/2020ArgusUpgradeHold ➝ Buy$91.40 ➝ $115.00Low
i
5/28/2020Royal Bank of CanadaReiterated RatingBuy$102.00Low
i
5/18/2020Bank of AmericaInitiated CoverageNeutral$95.00Low
i
5/12/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$105.00Medium
i
5/11/2020Morgan StanleyReiterated RatingOverweight$95.00High
i
5/11/2020SVB LeerinkBoost Price TargetOutperform$107.00 ➝ $122.00High
i
5/4/2020SVB LeerinkBoost Price TargetOutperform$103.00 ➝ $107.00Low
i
5/1/2020MizuhoReiterated RatingBuy$100.00Medium
i
Rating by Vamil Divan at Mizuho
4/20/2020Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$79.00 ➝ $93.00Low
i
4/13/2020UBS GroupLower Price TargetBuy$106.00 ➝ $96.00Low
i
4/12/2020Royal Bank of CanadaReiterated RatingHold$79.00Low
i
3/23/2020Societe GeneraleDowngradeBuy ➝ HoldHigh
i
2/27/2020BarclaysInitiated CoverageEqual Weight$97.00 ➝ $97.00High
i
2/18/2020CowenBoost Price TargetOutperform$98.00 ➝ $105.00Low
i
Rating by Steve Scala at Cowen Inc
2/10/2020MizuhoBoost Price Target$96.00 ➝ $104.00High
i
Rating by Vamil Divan at Mizuho
2/7/2020Piper SandlerBoost Price TargetOverweight$95.00 ➝ $97.00Low
i
2/5/2020MizuhoInitiated CoverageBuy$96.00 ➝ $96.00Low
i
1/23/2020Royal Bank of CanadaReiterated RatingHold$86.00High
i
1/6/2020Royal Bank of CanadaInitiated CoverageSector Perform$86.00Low
i
1/3/2020Bank of AmericaDowngradeBuy ➝ NeutralLow
i
12/26/2019CowenBoost Price TargetOutperform$90.00 ➝ $98.00Low
i
Rating by Steve Scala at Cowen Inc
11/20/2019CitigroupBoost Price TargetBuy$90.00 ➝ $98.00Medium
i
Rating by Andrew Baum at Citigroup Inc.
11/19/2019UBS GroupBoost Price TargetBuy$79.00 ➝ $96.00High
i
Rating by Navin Jacob at UBS Group AG
11/1/2019Piper Jaffray CompaniesBoost Price Target$81.00 ➝ $90.00High
i
Rating by Christopher Raymond at Piper Jaffray Companies
9/26/2019CitigroupUpgradeNeutral ➝ Buy$87.00 ➝ $90.00Medium
i
Rating by Andrew Baum at Citigroup Inc.
9/24/2019CowenSet Price TargetBuy$90.00Low
i
Rating by Steve Scala at Cowen Inc
9/12/2019UBS GroupUpgradeNeutral ➝ Buy$85.00 ➝ $79.00Low
i
9/4/2019Piper Jaffray CompaniesBoost Price TargetOverweight$80.00 ➝ $81.00Medium
i
Rating by Christopher Raymond at Piper Jaffray Companies
8/20/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$80.00High
i
Rating by Christopher Raymond at Piper Jaffray Companies
7/26/2019Piper Jaffray CompaniesSet Price TargetHold$80.00N/A
i
Rating by Christopher Raymond at Piper Jaffray Companies
7/2/2019SVB LeerinkUpgradeBuyLow
i
Rating by Geoff Porges at SVB Leerink LLC
6/27/2019Wolfe ResearchUpgradeUnderperform ➝ Peer PerformMedium
i
6/26/2019CitigroupReiterated RatingHoldMedium
i
Rating by Andrew Baum at Citigroup Inc.
6/26/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$88.00High
i
Rating by G. Porges at SVB Leerink LLC
5/28/2019The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$84.00High
i
4/28/2019BMO Capital MarketsUpgradeUnderperform ➝ Market Perform$71.00 ➝ $79.00Low
i
4/26/2019Credit Suisse GroupSet Price TargetSell$78.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
3/25/2019ArgusDowngradeBuy ➝ HoldLow
i
2/14/2019BarclaysReiterated RatingHold$86.00Low
i
1/25/2019Credit Suisse GroupSet Price TargetHold$79.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
1/23/2019UBS GroupReiterated RatingNeutral ➝ Neutral$97.00 ➝ $91.00Low
i
1/17/2019Credit Suisse GroupUpgradeHold$79.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
1/3/2019Bank of AmericaDowngradeBuy ➝ NeutralMedium
i
Rating by Jason Gerberry at Bank of America Co.
12/26/2018Standpoint ResearchInitiated CoverageBuy ➝ BuyHigh
i
12/20/2018Morgan StanleySet Price TargetHold$88.00High
i
Rating by David Risinger at Morgan Stanley
11/6/2018ArgusLower Price TargetBuy ➝ Buy$130.00 ➝ $115.00Low
i
11/5/2018BMO Capital MarketsLower Price TargetUnderperform ➝ Underperform$78.00 ➝ $71.00Low
i
11/4/2018BarclaysReiterated RatingHold$90.00High
i
11/2/2018Credit Suisse GroupSet Price TargetHold$85.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
10/23/2018Wolfe ResearchInitiated CoverageUnderperformLow
i
10/22/2018SunTrust BanksLower Price TargetBuy ➝ Buy$157.00 ➝ $135.00High
i
10/20/2018Credit Suisse GroupSet Price TargetSell$85.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
10/14/2018Credit Suisse GroupSet Price TargetHold$85.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
10/4/2018Bank of AmericaLower Price TargetBuy ➝ Buy$107.00 ➝ $106.00Medium
i
8/22/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$105.00 ➝ $107.00Low
i
Rating by Jason Gerberry at Bank of America Co.
8/22/2018BMO Capital MarketsReiterated RatingSell$78.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
7/30/2018Bank of AmericaLower Price TargetBuy ➝ Buy$112.00 ➝ $105.00Medium
i
Rating by Jason Gerberry at Bank of America Co.
7/27/2018Piper Jaffray CompaniesReiterated RatingHold$100.00Low
i
7/27/2018CowenSet Price TargetBuy$110.00Low
i
Rating by Steve Scala at Cowen Inc
7/27/2018BMO Capital MarketsReiterated RatingSell$78.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
7/15/2018Jefferies Financial GroupSet Price TargetBuy$100.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
7/13/2018Credit Suisse GroupUpgradeHold$89.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
7/12/2018Berenberg BankInitiated CoverageHold$105.00Low
i
6/11/2018ArgusLower Price TargetBuy ➝ Buy$145.00 ➝ $130.00Low
i
6/6/2018Credit Suisse GroupSet Price TargetSell$89.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
6/1/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$125.86 ➝ $66.62Low
i
Rating by Richard Purkiss at Piper Jaffray Companies
5/30/2018Deutsche BankDowngradeNeutral ➝ Underperform$125.86 ➝ $65.61Medium
i
5/30/2018Deutsche Bank AktiengesellschaftDowngradeNeutral ➝ Underperform$125.86 ➝ $65.61Low
i
5/29/2018Credit Suisse GroupDowngradeNeutral ➝ Sell$104.00 ➝ $89.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
5/24/2018The Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyHigh
i
5/23/2018BMO Capital MarketsLower Price TargetUnderperform ➝ Underperform$81.00 ➝ $78.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
5/1/2018BMO Capital MarketsReiterated RatingSell$81.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
4/30/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$131.00 ➝ $110.00High
i
Rating by David Risinger at Morgan Stanley
4/27/2018Credit Suisse GroupLower Price TargetNeutral ➝ Neutral$109.00 ➝ $104.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
4/22/2018Credit Suisse GroupSet Price TargetHold$109.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
4/13/2018Jefferies Financial GroupSet Price TargetBuy$122.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
4/10/2018Credit Suisse GroupSet Price TargetHold$109.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
4/5/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$120.00 ➝ $102.00Low
i
4/5/2018BMO Capital MarketsReiterated RatingSell$80.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
3/26/2018Bank of AmericaSet Price TargetHold$120.00High
i
Rating by Jason Gerberry at Bank of America Co.
3/23/2018Jefferies Financial GroupSet Price TargetBuy$125.00High
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
3/23/2018Credit Suisse GroupLower Price TargetNeutral$109.00 ➝ $98.10Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
3/23/2018BMO Capital MarketsLower Price TargetUnderperform ➝ Underperform$95.00 ➝ $80.00Medium
i
Rating by Alex Arfaei at BMO Capital Markets
3/22/2018BMO Capital MarketsSet Price TargetSell$95.00High
i
Rating by Alex Arfaei at BMO Capital Markets
3/13/2018BMO Capital MarketsSet Price TargetSell$95.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
2/26/2018Jefferies Financial GroupSet Price TargetBuy$145.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
2/21/2018BMO Capital MarketsSet Price TargetSell$95.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
2/15/2018BMO Capital MarketsReiterated RatingSell$95.00High
i
Rating by Alex Arfaei at BMO Capital Markets
2/15/2018Piper Jaffray CompaniesBoost Price TargetOverweight$130.00 ➝ $138.00High
i
Rating by Richard Purkiss at Piper Jaffray Companies
2/2/2018ArgusBoost Price TargetBuy$120.00 ➝ $145.00Low
i
1/30/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$99.00 ➝ $131.00Low
i
1/29/2018Evercore ISIReiterated RatingBuy$144.00Low
i
1/29/2018Credit Suisse GroupSet Price TargetHold$98.00 ➝ $135.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
1/29/2018BMO Capital MarketsDowngradeMarket Perform ➝ Underperform$125.86 ➝ $84.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
1/29/2018SunTrust BanksBoost Price TargetBuy ➝ Average$157.00Low
i
1/29/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$127.00Medium
i
Rating by Geoff Porges at SVB Leerink LLC
1/26/2018Piper Jaffray CompaniesBoost Price TargetOutperform$115.00 ➝ $130.00Low
i
Rating by Richard Purkiss at Piper Jaffray Companies
1/22/2018Credit Suisse GroupSet Price TargetHold$98.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
1/11/2018BMO Capital MarketsSet Price TargetHold$84.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
1/4/2018Jefferies Financial GroupBoost Price TargetBuy$115.00 ➝ $120.00Low
i
1/2/2018Piper Jaffray CompaniesReiterated RatingBuyHigh
i
Rating by Richard Purkiss at Piper Jaffray Companies
12/20/2017BMO Capital MarketsSet Price TargetHold$84.00Medium
i
Rating by Alex Arfaei at BMO Capital Markets
12/5/2017SVB LeerinkSet Price TargetBuy$106.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
12/4/2017BMO Capital MarketsSet Price TargetHold$84.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
11/21/2017BMO Capital MarketsReiterated RatingHold$84.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
11/21/2017Societe GeneraleBoost Price TargetN/A
i
10/30/2017SunTrust BanksReiterated RatingBuyN/A
i
10/30/2017SVB LeerinkLower Price TargetOutperform$108.00 ➝ $107.00N/A
i
Rating by G. Porges at SVB Leerink LLC
10/27/2017BMO Capital MarketsSet Price TargetHold$66.00N/A
i
10/27/2017Piper Jaffray CompaniesBoost Price TargetOverweight$115.00N/A
i
10/16/2017Jefferies Financial GroupBoost Price TargetBuy$107.00 ➝ $115.00N/A
i
10/13/2017BarclaysBoost Price TargetEqual Weight$90.00N/A
i
10/13/2017UBS GroupReiterated RatingNeutralN/A
i
10/11/2017CowenUpgradeMarket Perform ➝ Outperform$91.17 ➝ $105.00N/A
i
10/2/2017SVB LeerinkUpgradeMarket Perform ➝ Outperform$89.00 ➝ $106.00Medium
i
Rating by G. Porges at SVB Leerink LLC
10/1/2017Credit Suisse GroupReiterated RatingNeutral$74.00 ➝ $94.00Medium
i
9/30/2017Evercore ISIReiterated RatingOutperform$95.00 ➝ $100.00Medium
i
9/29/2017ArgusBoost Price TargetBuy$90.00 ➝ $110.00Low
i
9/29/2017Morgan StanleyBoost Price TargetEqual Weight$70.00 ➝ $95.00Low
i
9/28/2017BarclaysReiterated RatingHold$68.00Low
i
9/28/2017BMO Capital MarketsReiterated RatingHold$66.00Low
i
9/28/2017Deutsche Bank AktiengesellschaftBoost Price TargetHold$88.00Low
i
9/28/2017Jefferies Financial GroupReiterated RatingBuy$107.00Medium
i
9/25/2017UBS GroupDowngradeBuy ➝ Neutral$79.00 ➝ $92.00Low
i
9/15/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$94.00 ➝ $107.00High
i
9/15/2017Piper Jaffray CompaniesReiterated RatingBuy$100.00High
i
9/13/2017SunTrust BanksReiterated RatingBuy$95.00Low
i
9/12/2017SVB LeerinkReiterated RatingMarket PerformLow
i
9/11/2017CowenReiterated RatingMarket Perform ➝ Hold$70.00 ➝ $95.00Medium
i
9/8/2017The Goldman Sachs GroupReiterated RatingBuy$85.00 ➝ $100.00Low
i
9/8/2017Jefferies Financial GroupReiterated RatingBuy$94.00Low
i
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$95.00Medium
i
8/3/2017Piper Jaffray CompaniesReiterated RatingBuy$85.00Low
i
7/30/2017CowenSet Price TargetHold$70.00Low
i
7/20/2017Credit Suisse GroupReiterated RatingNeutral$65.00 ➝ $74.00Medium
i
7/17/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$65.00 ➝ $66.00Low
i
7/17/2017Jefferies Financial GroupReiterated RatingBuy$92.00 ➝ $94.00Low
i
6/22/2017SVB LeerinkReiterated RatingMarket PerformLow
i
6/22/2017Societe GeneraleUpgradeHold ➝ BuyLow
i
6/7/2017Credit Suisse GroupReiterated RatingHold$65.00Medium
i
5/26/2017Jefferies Financial GroupReiterated RatingBuyN/A
i
5/17/2017BMO Capital MarketsReiterated RatingMarket Perform$66.00Low
i
5/2/2017BMO Capital MarketsBoost Price TargetMarket Perform$63.00 ➝ $66.00Low
i
4/28/2017Deutsche Bank AktiengesellschaftBoost Price TargetHold$64.00 ➝ $65.00Low
i
4/27/2017BMO Capital MarketsSet Price TargetHold$63.00Medium
i
4/20/2017SVB LeerinkSet Price TargetHold$71.00Low
i
Rating by G. Porges at SVB Leerink LLC
4/18/2017BMO Capital MarketsReiterated RatingHold$63.00Low
i
3/22/2017Societe GeneraleUpgradeSell ➝ HoldLow
i
3/22/2017BMO Capital MarketsReiterated RatingHold$63.00Low
i
3/11/2017The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$74.00 ➝ $80.00N/A
i
3/7/2017Jefferies Financial GroupReiterated RatingTop Pick ➝ Buy$4.30 ➝ $90.00N/A
i
2/14/2017Jefferies Financial GroupReiterated RatingBuy$90.00N/A
i
1/5/2017Jefferies Financial GroupReiterated RatingBuy$90.00N/A
i
12/8/2016William BlairReiterated RatingOutperform$76.00N/A
i
11/28/2016CitigroupDowngradeBuy ➝ Neutral$60.00N/A
i
11/8/2016SVB LeerinkReiterated RatingHoldN/A
i
Rating by G. Porges at SVB Leerink LLC
11/8/2016BMO Capital MarketsReiterated RatingMarket Perform$63.00N/A
i
11/8/2016CitigroupReiterated RatingBuyN/A
i
11/1/2016Jefferies Financial GroupReiterated RatingBuy$90.00N/A
i
10/31/2016Credit Suisse GroupDowngradeOutperform ➝ Neutral$70.00 ➝ $60.00N/A
i
10/18/2016SVB LeerinkInitiated CoverageMarket Perform$70.00N/A
i
Rating by G. Porges at SVB Leerink LLC
10/5/2016Jefferies Financial GroupReiterated RatingBuy$90.00N/A
i
9/27/2016The Goldman Sachs GroupReiterated RatingBuy$78.00N/A
i
9/8/2016The Goldman Sachs GroupReiterated RatingBuy$78.00N/A
i
9/8/2016JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$75.00 ➝ $73.00N/A
i
9/7/2016UBS GroupReiterated RatingBuyN/A
i
9/1/2016Raymond JamesInitiated CoverageOutperform$82.00N/A
i
8/25/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
8/8/2016ArgusReiterated RatingBuy$85.00N/A
i
8/4/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
8/2/2016BarclaysReiterated RatingEqual Weight$68.00N/A
i
7/29/2016BMO Capital MarketsReiterated RatingMarket Perform$66.00N/A
i
7/10/2016Credit Suisse GroupReiterated RatingBuyN/A
i
6/29/2016Credit Suisse GroupReiterated RatingOutperform$67.00N/A
i
6/15/2016UBS GroupReiterated RatingBuy$73.00N/A
i
6/10/2016BMO Capital MarketsDowngradeOutperform ➝ Market Perform$70.00 ➝ $66.00N/A
i
6/8/2016Morgan StanleyDowngradeOverweight ➝ Equal Weight$73.00 ➝ $65.00N/A
i
6/7/2016Deutsche Bank AktiengesellschaftReiterated RatingHoldN/A
i
6/6/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
6/6/2016Morgan StanleyDowngradeOverweight ➝ Equal Weight$73.00 ➝ $65.00N/A
i
6/6/2016UBS GroupReiterated RatingBuyN/A
i
6/6/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
6/6/2016CowenDowngradeOutperform ➝ Market Perform$77.00 ➝ $70.00N/A
i
5/18/2016Deutsche Bank AktiengesellschaftReiterated RatingHold$66.00N/A
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
5/18/2016BMO Capital MarketsReiterated RatingOutperform$70.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
5/13/2016Jefferies Financial GroupReiterated RatingBuy$90.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
5/3/2016BMO Capital MarketsReiterated RatingBuyN/A
i
Rating by Alex Arfaei at BMO Capital Markets
4/30/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by David Risinger at Morgan Stanley
4/29/2016Jefferies Financial GroupReiterated RatingBuy$90.00N/A
i
4/26/2016Credit Suisse GroupReiterated RatingOverweightN/A
i
4/6/2016Societe GeneraleInitiated CoverageSell$47.00N/A
i
3/15/2016Deutsche Bank AktiengesellschaftInitiated CoverageHold$63.00N/A
i
3/10/2016Jefferies Financial GroupReiterated RatingBuy$80.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
3/7/2016The Goldman Sachs GroupDowngradeConviction-Buy ➝ Buy$80.00 ➝ $68.00N/A
i
Rating by Jami Rubin at The Goldman Sachs Group, Inc.
2/23/2016Jefferies Financial GroupReiterated RatingBuy$80.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
2/23/2016CitigroupUpgradeNeutral ➝ Buy$56.00 ➝ $65.00N/A
i
Rating by Andrew Baum at Citigroup Inc.
2/6/2016William BlairReiterated RatingBuyN/A
i
Rating by Y Katherine Xu at William Blair
2/5/2016Credit Suisse GroupLower Price Target$69.00 ➝ $67.00N/A
i
2/5/2016William BlairInitiated CoverageOutperform$76.00N/A
i
Rating by Y. Xu at William Blair
1/27/2016BMO Capital MarketsLower Price TargetOutperform$70.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
1/25/2016Credit Suisse GroupReiterated RatingOutperformN/A
i
1/15/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by David Risinger at Morgan Stanley
1/15/2016BMO Capital MarketsReiterated RatingBuy$77.00N/A
i
1/14/2016Jefferies Financial GroupLower Price TargetBuy$85.00 ➝ $80.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$59.00N/A
i
12/17/2015Credit Suisse GroupLower Price Target$75.00 ➝ $69.00N/A
i
12/11/2015Credit Suisse GroupLower Price TargetOutperform$78.00 ➝ $75.00N/A
i
12/3/2015CowenReiterated RatingOutperform$75.00 ➝ $70.00N/A
i
Rating by Steve Scala at Cowen Inc
12/1/2015BarclaysDowngradeOverweight ➝ Equal Weight$73.00 ➝ $72.00N/A
i
11/10/2015ArgusReiterated RatingBuy$85.00 ➝ $63.23N/A
i
11/2/2015UBS GroupReiterated RatingBuy$78.00N/A
i
Rating by Marc Goodman at UBS Group AG
11/2/2015Credit Suisse GroupBoost Price TargetOutperform$77.00 ➝ $78.00N/A
i
11/2/2015Morgan StanleyUpgradeEqual Weight ➝ Overweight$62.00 ➝ $73.00N/A
i
Rating by David Risinger at Morgan Stanley
10/30/2015CowenReiterated RatingBuyN/A
i
Rating by Steve Scala at Cowen Inc
(Data available from 10/29/2015 forward)
AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Read More

Today's Range

Now: $80.67
$79.11
$81.37

50 Day Range

MA: $87.03
$80.49
$91.63

52 Week Range

Now: $80.67
$62.55
$101.28

Volume

8,657,860 shs

Average Volume

9,652,167 shs

Market Capitalization

$142.37 billion

P/E Ratio

17.16

Dividend Yield

5.86%

Beta

0.74